Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double umbilical cord blood transplantation in high-risk hematologic patients
NL-OMON22961Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Aug 2012
- Modality
- Small Molecules, Peptides, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of umbilical cord blood-derived regulatory T cells, mycophenolate mofetil and cyclosporine in hematopoietic malignancies and aplastic anemia, sponsored by HOVON. Primary endpoint: Proportion of patients with activated class II-specific T-cells. Started Aug 2012; status: recruiting.
02
Drugs
umbilical cord blood-derived regulatory T cellsmycophenolate mofetilcyclosporine
03
Conditions
hematopoietic malignanciesaplastic anemia
Beyond the preview
Go deeper on NL-OMON22961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22961.